Literature DB >> 9130910

Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis.

M E Fallat1, Y Siow, M Marra, C Cook, A Carrillo.   

Abstract

OBJECTIVE: To determine Müllerian inhibiting substance (MIS) levels in follicular fluid (FF) and sera of IVF patients.
DESIGN: Prospective study.
SETTING: Fertility center. PATIENT(S): Sixty-six patients: 20 with tubal factor infertility, 17 with polycystic ovary syndrome (PCOS), and 29 with endometriosis. INTERVENTION(S): All patients underwent ovarian stimulation with hMG and/or FSH, as well as oocyte retrieval for IVF. MAIN OUTCOME MEASURE(S): Follicular fluid and serum MIS levels and oocyte fertilization rates. RESULT(S): Levels of MIS in FF and sera of PCOS patients were significantly higher than those in tubal factor patients: 7.01 +/- 1.52 versus 1.65 +/- 0.23 ng/mL (mean +/- SE) and 2.97 +/- 0.52 versus 0.92 +/- 0.19 ng/mL, respectively. In endometriosis patients, follicular fluid and serum MIS levels were not significantly different from those in tubal factor patients. In PCOS patients, the percentage of immature oocytes retrieved (17.9% +/- 5.0%) was significantly higher compared with tubal factor (1.5% +/- 1.0%) and endometriosis (9.2% +/- 2.3%) patients. The percentage of oocytes fertilize was significantly lower in PCOS patients (30.2% +/- 5.3%) compared with tubal factor (62.2% +/- 5.5%) and endometriosis (37.5% +/- 5.7%) patients. CONCLUSION(S): Women with PCOS had higher serum and follicular fluid MIS levels, a higher percentage of immature oocytes, and lower fertilization rates than women with endometriosis or pelvic adhesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130910     DOI: 10.1016/s0015-0282(97)81417-3

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  24 in total

Review 1.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

Review 2.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 3.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 4.  Blood biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull
Journal:  Cochrane Database Syst Rev       Date:  2016-05-01

Review 5.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

6.  Follicular fluid anti-Müllerian hormone (AMH) concentrations and outcomes of in vitro fertilization cycles with fresh embryo transfer among women at a fertility center.

Authors:  Caitlin R Sacha; Jorge E Chavarro; Paige L Williams; Jennifer Ford; LiHua Zhang; Patricia K Donahoe; Irene C Souter; Russ Hauser; David Pépin; Lidia Mínguez-Alarcón
Journal:  J Assist Reprod Genet       Date:  2020-10-06       Impact factor: 3.412

7.  The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome.

Authors:  A Michael Wallace; Naveed Sattar
Journal:  Clin Biochem Rev       Date:  2007-08

8.  Lack of Serum anti-Mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome.

Authors:  Heidi Cook-Andersen; Sandy S Chuan; Kevin Maas; Marcus A Rosencrantz; H Irene Su; Mark Lawson; Helen D Mason; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

9.  The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women.

Authors:  Leif Bungum; Florencia Franssohn; Mona Bungum; Peter Humaidan; Aleksander Giwercman
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

10.  Prediction of reproductive outcomes according to different serum anti-Müllerian hormone levels in females undergoing intracystoplasmic sperm injection.

Authors:  Santiago Brugo Olmedo; Sabrina De Vincentiis; Evelyn De Martino; Patricia Bedecarrás; Ana María Blanco; Analía Freire; Mariano G Buffone; Rodolfo A Rey
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.